QCZ484

Phase 2Small molecule

Novartis

QCZ484 is one of 29 small molecule programs targeting Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionActive, not recruiting

HypercholesterolaemiaRecruiting

Hypertension (HTN)Recruiting

HypertensionPhase 2

Active, not recruiting

HypercholesterolaemiaPhase 2

Recruiting

Hypertension (HTN)Phase 2

Recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Apresoline

Novartis

Preclinical

7 2

Zebeta

Teva

Preclinical

6 3

Edarbi

Takeda

Preclinical

4 4

QCZ484

Novartis

Phase 2

2 5

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 6

Winrevair

Alphagan

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 9

Disalcid

JJoslin Diabetes Center

Preclinical

1 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Hypercholesterolaemia

NCT07610278

Q2 2028

Phase 2Active, not recruiting

Hypertension

NCT06857955

Q4 2031

Phase 2Recruiting

Hypertension (HTN)

NCT07543120

Clinical

Trials by Indication[1]

Hypertension2 trials

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered QCZ484 in Healthy Subjects and Subjects With Mild Hypertension

Completed· Novartis logo

Novartis·Phase 1·NCT06905327·56 enrolled

A Randomized, Double-blind, Placebo-controlled, Multicenter, 12 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of QCZ484 in Mild to Moderate Hypertensive Patients

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT06857955·399 enrolled

Hypertension (HTN)1 trial

A Multicenter Open-label Extension Study to Evaluate Long-term Safety and Efficacy of QCZ484 in Hypertensive Patients.

Recruiting· Novartis logo

Novartis·Phase 2·NCT07543120·323 enrolled

Hypercholesterolaemia1 trial

A Multicenter, Randomized, Double-blind, Factorial Design Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of HDY015 Administered as a Free Combination of QCZ484 and Inclisiran Compared to QCZ484, Inclisiran, and Placebo in Participants With Hypertension and Concomitant Hypercholesterolemia

Recruiting· Novartis logo

Novartis·Phase 2·NCT07610278·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for QCZ484. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QCZ484 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QCZ484. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

QCZ484

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Q4 2031

Trials by Indication[1]

Hypertension2 trials

Hypertension (HTN)1 trial

Hypercholesterolaemia1 trial

References

Drug Info

Quick Facts

Related News